AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy

被引：0

作者：

Kagiava, A. ^{[1
,2
]}

Karaiskos, C. ^{[1
,2
]}

Lapathitis, G. ^{[1
,2
]}

Sargiannidou, I. ^{[1
,2
]}

Bosch, A. ^{[3
]}

Kleopa, K. A. ^{[1
,2
,4
,5
]}

机构：

[1] Cyprus Inst Neurol & Genet, Dept Neurosci, Engomi, Cyprus

[2] Cyprus Sch Mol Med, Engomi, Cyprus

[3] Univ Autonoma Barcelona, Inst Neurosci, Dept Biochem & Mol Biol, Barcelona, Spain

[4] Cyprus Inst Neurol & Genet, Ctr Neuromuscular Disorders, Engomi, Cyprus

[5] Cyprus Sch Mol Med, Engomi, Cyprus

来源：

HUMAN GENE THERAPY | 2021年 / 32卷 / 19-20期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

P305

引用

页码：A121 / A122

页数：2

共 50 条

[41] AAV9-KDAR GENE THERAPY IS A PROMISING TREATMENT APPROACH FOR CMT1B [J].

Munezero, Daniella ;

Paripati, Arun ;

Zhu, Jingting ;

Chuah, Russell ;

Rashnonejad, Afrooz .

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 :S161-S162

[42] AAV9 Intravenous Gene Therapy Enhanced Motor, Cognitive Function and Survival in a Mouse Model of Neuropathic Gaucher Disease [J].

Lin, Yi ;

Kilbane, Brianna ;

DeMott, Jacob ;

Zhang, Zhenting ;

Wang, Xiaohong ;

Liou, Benjamin ;

Sun, Ying ;

Xiao, Weidong ;

Pan, Dao .

MOLECULAR THERAPY, 2019, 27 (04) :366-367

[43] Developmental Age Effects for AAV9/ SLC6A1 Gene Therapy in a Mouse Model of SLC6A1 Related Disorder [J].

Guo, Weirui ;

Rioux, Matthew Colby ;

Shaffo, Frances ;

Hu, Yuhui ;

Gray, Steven J. .

MOLECULAR THERAPY, 2023, 31 (04) :344-344

[44] Early Intervention with Intravenous AAV9 Gene Therapy Significantly Improves Biomarkers and Phenotypes in a Floxed Mouse Model of X-linked Alport Syndrome [J].

Nakai, Hiroyuki ;

Das, Ranjan ;

Furusho, Taisuke ;

Sairavi, Anusha ;

Hakui, Hideyuki ;

Luo Shuhua ;

Li, Lena ;

Miner, Jeffrey H. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10)

[45] AAV9 gene replacement therapy for respiratory insufficiency in very-long chain acyl-CoA dehydrogenase deficiency [J].

Zieger, Marina ;

Keeler, Allison M. ;

Flotte, Terence R. ;

ElMallah, Mai K. .

JOURNAL OF INHERITED METABOLIC DISEASE, 2019, 42 (05) :870-877

[46] Optimization of Systemic AAV9 Gene Therapy in Niemann-Pick Type C1 Mice [J].

Mylvara, Avani ;

Davidson, Cristin ;

Gu, Tansy ;

Gibson, Alana L. ;

Baxter, Laura ;

Incao, Art ;

Venditti, Charles P. ;

Pavan, William ;

Porter, Forbes D. .

MOLECULAR THERAPY, 2024, 32 (04) :732-732

[47] Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin [J].

Cheah, Pike-See ;

Prabhakar, Shilpa ;

Yellen, David ;

Beauchamp, Roberta L. ;

Zhang, Xuan ;

Kasamatsu, Shingo ;

Bronson, Roderick T. ;

Thiele, Elizabeth A. ;

Kwiatkowski, David J. ;

Stemmer-Rachamimov, Anat ;

Gyorgy, Bence ;

Lin, King-Hwa ;

Kaneki, Masao ;

Tannous, Bakhos A. ;

Ramesh, Vijaya ;

Maguire, Casey A. ;

Breakefield, Xandra O. .

SCIENCE ADVANCES, 2021, 7 (02)

[48] NON-HUMAN PRIMATE BIODISTRIBUTION AND SAFETY STUDY SUPPORTS TRANSLATION OF AAV9-MEDIATED GENE SILENCING THERAPY FOR CMT1A NEUROPATHY [J].

Stavrou, Marina ;

Wallace, Lindsay ;

Price, Brian ;

Thangaraj, Merlin ;

Harper, Scott ;

Kleopa, Kleopas .

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 :S163-S164

[49] Gene Therapy for Tuberous Sclerosis Complex Type 2 in a Mouse Model by Delivery of AAV9 Encoding a Condensed Form of Tuberin [J].

Prabhakar, Shilpa .

MOLECULAR THERAPY, 2020, 28 (04) :563-563

[50] A dose escalation and safety study of AAVrh10-mediated Schwann cell-targeted gene therapy for CMT1X [J].

Christou, Melina ;

Sargiannidou, Irene ;

Papacharalambous, Revekka ;

Richter, Jan ;

Tryfonos, Christina ;

Christodoulou, Christina ;

Kagiava, Alexia ;

Kleopa, Kleopas A. .

NEUROTHERAPEUTICS, 2025, 22 (03)

← 1 2 3 4 5 →